A man living with cancer died after being given multiple overdoses of morphine
CPD articles
Image
Identifying best transition practice for young adults who had childhood cancer
Image
Learn more about the experience of pain in patients living with and beyond cancer
Image
The principles of prehabilitation in cancer care and its benefits for people with cancer
Image
Outline of the WHO classification of such tumours, and their treatment and predicted outcomes
Image
A reflection on health risks associated with handling systemic anticancer therapy agents
Image
Use of CDK4 and CDK6 inhibitors in patients with breast cancer
Image
Oral complications can cause distress, long-term complications and increased morbidity
Image
A systematic approach for nurses at any level or experience to engage with service evaluation
Image
Receiving a new diagnosis of cancer or of its recurrence is distressing and there are incr
Image
There is increasing recognition of the importance of mak
Image
Advance care planning (ACP) is a process of establishing a person’s p
Treatment regimens involving the monoclonal anti-CD20 antibody rituximab are the standard of care for patients with CD20-positive non-Hodgkin lymphoma (NHL). It has conventionally been given by intravenous (IV) infusion, which requires intermittent patient monitoring during administration.
Nurses should understand the role and purpose of the new generation of therapies available for patients with cancer. One such drug is the poly (ADP-ribose) polymerase inhibitor olaparib (Lynparza™▼).
This article provides nurses with an update on diagnosis, management and care of patients with myelodysplastic syndromes (MDS), a complex group of disorders of the bone marrow. MDS has wide-ranging effects on patients’ lives.
Preventing medication errors is essential to maintain a safe healthcare system
Survivorship is an important issue in cancer care in the UK. More people are being diagnosed with the disease and many more are living for longer after diagnosis.
Non-Hodgkin’s lymphoma is a heterogeneous group of lymphoproliferative malignancies with differing patterns of behaviour and responses to treatment.
